Fatty Liver
176
18
22
91
Key Insights
Highlights
Success Rate
86% trial completion
Published Results
23 trials with published results (13%)
Research Maturity
91 completed trials (52% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.5%
15 terminated out of 176 trials
85.8%
-0.7% vs benchmark
13%
23 trials in Phase 3/4
25%
23 of 91 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 91 completed trials
Clinical Trials (176)
Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease
Association Between Fatty Liver and Inflammatory Biomarkers
Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women
Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population
Early Tracking of Childhood Health Determinants (ETCHED) Study
The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology
Impact of Ganoderma Lucidum on NRF2 Levels and Antioxidant Status in Metabolic Asscociated Fatty Liver Disease (GL-MAFLD-NRF2 Study)
Samsung S-Viscosity vs Canon Dispersion Slope in Steatotic Liver Disease (SAVID-SLD)
Siemens Biomarker Multi-modality
Assessment of Fatty Liver With Thermo-acoustic Device
Effects of Short-Term Resistance Training on Diaphragm Thickness, Hepatic Fat Density, and Quality of Life in Healthy Older Men
GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease
Personalized Transcranial Magnetic Stimulation (TMS) for Metabolic Dysfunction and Alcohol-Related Liver Disease
Single-Cell and Spatial Transcriptomics Analysis of Steatotic Donor Liver Susceptibility to Post-Transplant Injury
Intermittent Fasting for NAFLD in Adults
Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease
Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)